Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Johnathan Warminski

Ophthalmology Southlake, TX Medical Doctor

NPI 1760618250 CMS profile 216271

305 Morrison Park Dr Ste 100, Southlake, TX 76092

Open in the dashboard

General payments

$6,324

265 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Johnathan Warminski of Southlake, TX is reported in the CMS Open Payments database as having received $6,324 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,929 86
2024 General $1,864 76
2023 General $1,447 59
2022 General $753 32
2021 General $114 6
2020 General $21 1
2019 General $196 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Johnathan Warminski
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Johnathan Warminski were reported at $1,929. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Johnathan Warminski Ophthalmology median Middle half National median
2019 $196 $258 $104–$655 $163
2020 $21 $126 $45–$321 $114
2021 $114 $205 $76–$534 $132
2022 $753 $266 $100–$678 $149
2023 $1,447 $308 $117–$745 $160
2024 $1,864 $340 $127–$846 $164
2025 $1,929 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $1,193 46 payments
  2. Genentech USA, Inc. $979 50 payments
  3. AbbVie, Inc. $859 35 payments
  4. Astellas Pharma US Inc $718 30 payments
  5. Bausch & Lomb Americas Inc. $536 25 payments
  6. Apellis Pharmaceuticals, Inc. $487 19 payments
  7. ANI Pharmaceuticals, Inc. $392 15 payments
  8. Coherus Biosciences Inc. $200 7 payments
  9. Alimera Sciences, Inc. $186 9 payments
  10. Sandoz Inc. $166 6 payments
  11. Other $608 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,309 264 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. VABYSMO $933 47 payments
  2. EYLEA HD $865 29 payments
  3. EYLEA $856 34 payments
  4. OZURDEX Eye Care $703 29 payments
  5. Izervay $647 27 payments
  6. Syfovre $442 17 payments
  7. Cimerli $337 12 payments
  8. XIPERE $311 14 payments
  9. ILUVIEN $301 12 payments
  10. OZURDEX Retina $266 7 payments
  11. Other $1,362 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

475

Median for Ophthalmology: 891

Drug cost

$24,683

Median for Ophthalmology: $68,233

Branded share of claims

62.1%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 115 $8,785
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 28 $4,771
Prednisolone Acetate Generic 77 $3,904
Combigan Brimonidine Tartrate/Timolol Brand 12 $3,823
Brimonidine Tartrate Generic 23 $1,239
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 47 $650
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 31 $586
Moxifloxacin Moxifloxacin Hcl Brand 16 $535
Promethazine Hcl Generic 80 $217
Acetaminophen-Codeine Acetaminophen With Codeine Brand 46 $172

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$5,248,040

Of which drugs: $4,235,026

Medicare patients

1,777

Average age 75

Services billed

120,706

973 women, 804 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 32%
Ischemic heart disease 27%
Chronic kidney disease 27%
Depression 20%
Atrial fibrillation 19%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, faricimab-svoa, 0.1 mg J2777 Office 292 95,474 $2,609,658
Injection, pegcetacoplan, intravitreal, 1 mg J2781 Office 62 7,376 $858,701
Injection, aflibercept, 1 mg J0178 Office 68 526 $339,065
Injection, avacincaptad pegol, 0.1 mg J2782 Office 19 2,501 $216,313
Injection, aflibercept hd, 1 mg J0177 Office 14 353 $92,771
Injection, triamcinolone acetonide (xipere), 1 mg J3299 Office 26 1,512 $57,560

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VABYSMO
  • Genentech USA, Inc. $382
$382 — 95,474
Izervay
  • Astellas Pharma US Inc $295
$295 — 2,501
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $245
$245 — 353
Cimerli
  • Sandoz Inc. $137
  • Coherus Biosciences Inc. $57
$194 — —
XIPERE
  • Bausch & Lomb Americas Inc. $172
$172 — 1,512

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record